Skip to main content
SpringerLink
Log in

Synthesis and Primary Antitumor Screening of 5-Ylidene Derivatives of 3-(Morpholin-4-yl)-2-sulfanylidene-1,3-thiazolidin-4-one

  • Published:
Russian Journal of Organic Chemistry Aims and scope Submit manuscript

Abstract

A preparative procedure has been developed for the synthesis of 3-(morpholin-4-yl)-2-sulfanylidene-1,3-thiazolidin-4-one (3-morpholinorhodanine). Its reaction with aldehydes afforded a number of previously unknown 5-ylidene derivatives which were screened for antitumor activity. The synthesized compounds showed a moderate activity against most malignant tumor cells. The renal cancer cell lines UO31 and TK10 were found to be most sensitive to all the tested compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme
Scheme

Similar content being viewed by others

REFERENCES

  1. Tomasić, T. and Masic, LP., Curr. Med. Chem., 2009, vol. 16, p. 1596. https://doi.org/10.2174/092986709788186200

    Article  PubMed  Google Scholar 

  2. Kaminskyy, D., Kryshchyshyn, A., and Lesyk, R., Expert Opin. Drug Discovery, 2017, vol. 12, p. 1233. https://doi.org/10.1080/17460441.2017.1388370

    Article  CAS  Google Scholar 

  3. Pal’chikov, V.A., Russ. J. Org. Chem., 2013, vol. 49, p. 787. https://doi.org/10.1134/S1070428013060018

    Article  CAS  Google Scholar 

  4. Mashkovskii, M.D., Lekarstvennye sredstva (Medicines), Moscow: Novaya Volna, 2010, 16th ed.

  5. Zimenkovskii, B.S., Kutsyk, R.V., Lesyk, R.B., Matyichuk, V.S., Obushak, N.D., and Klyufinska, T.I., Pharm. Chem. J., 2006, vol. 40, p. 303. https://doi.org/10.1007/s11094-006-0115-6

    Article  CAS  Google Scholar 

  6. Chaban, T.I., Klenina, O.V., Drapak, I., Ogurtsov, V.V., Chaban, I.G., and Novikov, V.P., Chem. Chem. Technol., 2014, vol. 8, p. 287.

    Article  CAS  Google Scholar 

  7. Tsyalkovsky, V.M., Kutsyk, R.V., Matiychuk, V.S., Obushak, N.D., and Klyufinskaya, T.I., Pharm. Chem. J., 2005, vol. 39, p. 245. https://doi.org/10.1007/s11094-005-0126-8

    Article  CAS  Google Scholar 

  8. Zelisko, N., Atamanyuk, D., Ostapiuk, Y., Bryhas, A., Matiychuk, V., Gzella, A., and Lesyk, R., Tetrahedron, 2015, vol. 71, p. 9501. https://doi.org/10.1016/j.tet.2015.10.019

    Article  CAS  Google Scholar 

  9. Chaban, T., Matiychuk, V., Ogurtsov, V., Chaban, I., Harkov, S., and Nektegaev, I., Pharmacia, 2018, vol. 65, p. 51.

    Google Scholar 

  10. Pokhodylo, N.T., Savka, R.D., Matiichuk, V.S., and Obushak, M.D.,Russ. J. Gen. Chem., 2009, vol. 79, p. 309. https://doi.org/10.1134/S1070363209020248

    Article  CAS  Google Scholar 

  11. Klenina, O., Chaban, T., Zimenkovsky, B., Harkov, S., Ogurtsov, V., Chaban, I., and Myrko, I., Pharmacia, 2017, vol. 64, p. 49.

    Google Scholar 

  12. Ostapiuk, Y.V., Obushak, M.D., Matiychuk, V.S., Naskrent, M., and Gzella, A.K., Tetrahedron Lett., 2012, vol. 53, p. 543. https://doi.org/10.1016/j.tetlet.2011.11.093

    Article  CAS  Google Scholar 

  13. Chaban, T.I., Ogurtsov, V.V., Matiychuk, V.S., Chaban, I.G., Demchuk, I.L., and Nektegayev, I.A., Acta Chim. Slov., 2019, vol. 66, p. 103. https://doi.org/10.17344/acsi.2018.4570

    Article  CAS  Google Scholar 

  14. Hanefeld, W. and Jalili, MA., Arch. Pharm., 1987, vol. 320, p. 329. https://doi.org/10.1002/ardp.19873200410

    Article  CAS  Google Scholar 

  15. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., and Vaigro-Wolff, A., J. Natl. Cancer Inst., 1991, vol. 83, p. 757. https://doi.org/10.1093/jnci/83.11.757

    Article  CAS  PubMed  Google Scholar 

  16. Boyd, M.R. and Paull, K.D., Drug Dev. Res., 1995, vol. 34, p. 91. https://doi.org/10.1002/ddr.430340203

    Article  CAS  Google Scholar 

  17. Wright, J.E., Therapeutics: Experimental and Clinical Agents, Teicher, B.A., Ed., Totowa NJ: Humana Press, 1997, p. 23. https://doi.org/10.1007/978-1-59259-717-8_2

  18. Shoemaker, R.H., Nature Rev. Cancer, 2006, vol. 6, p. 813. https://doi.org/10.1038/nrc1951

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Danila Halytsky Lviv National Medical University, 79010, Lviv, Ukraine

    V. Ya. Horishny & T. I. Chaban

  2. Ivan Franko Lviv National University, 79005, Lviv, Ukraine

    V. S. Matiychuk

Authors
  1. V. Ya. Horishny
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. I. Chaban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. S. Matiychuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. I. Chaban.

Ethics declarations

The authors declare the absence of conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horishny, V.Y., Chaban, T.I. & Matiychuk, V.S. Synthesis and Primary Antitumor Screening of 5-Ylidene Derivatives of 3-(Morpholin-4-yl)-2-sulfanylidene-1,3-thiazolidin-4-one. Russ J Org Chem 56, 454–457 (2020). https://doi.org/10.1134/S1070428020030148

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1070428020030148

Keywords:

Search

Navigation